The effect of treatment with recombinant human follicle stimulating hormone (rhFSH), human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) on semen parameters after varicocelectomy: a randomized clinical trial.

Comparison of the effects of treatment with recombinant human follicle stimulating hormone (rhFSH), human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) on semen parameters after varicocelectomy in patients with varicocele

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112248509N1

Enrollment

120

Registered

2012-01-06

Start date

2010-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility. Male infertility

Interventions

Intervention 1: Patients will be treated with 5000 IU human chorionic gonadotropin weekly intramuscular for 3 months. Intervention 2: Patients will be treated with 75 IU human menopausal gonadotropin

Treatment - Drugs

Patients will be treated with 5000 IU human chorionic gonadotropin weekly intramuscular for 3 months.

Patients will be treated with 75 IU human menopausal gonadotropin three times a week sub coutaneous for 3 months.

Patients will be treated with 75 IU recombinant human follicle-stimulating hormone three times a week sub coutaneous for 3 months.

no medical treatment after varicocelectomy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Inclusion criteria: infertility after 12 months of unprotected intercourse; male factor infertility due to varicocele; spontaneous onset of maturation and normal sexual development Exclusion criteria: presence of infertility due to any other factor especially female infertility; systemic disease; underlying testis abnormalities; abnormal reproductive hormone levels.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sperm parameters. Timepoint: before initiation of treatment and further control examinations were performed 8 to 10 weeks after the completion of each period of treatment. Method of measurement: spermogram.	—

Secondary

Measure	Time frame
Pregnancy. Timepoint: 6 month. Method of measurement: bHCG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Ali Amirzargar

Department of Urology, Hamadan University of Medical Sciences

dr_amirzargar@yahoo.com+98 81 1823 2858

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026